Response to: ‘Correspondence on ‘Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial’’ by Satis et al

Abstract

Listen

Translate article

We thank Satis et al 1 for their interest in our article,2 and will try to address their queries. Our colleagues suggest that flares with musculoskeletal symptoms as predominant signs...